Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries

Vaccine

Volumn 23, Issue 26, 2005, Pages 3369-3385

  Walker, Richard I ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Bacterial vaccines; Developing countries; Diarrheal diseases

Indexed keywords

ADJUVANT; ANTIGEN; BACTERIAL VACCINE; BUFFER; CHOLERA TOXIN; CHOLERA VACCINE; DRUG VEHICLE; ENTEROTOXIN; ESCHERICHIA COLI VACCINE; INACTIVATED VACCINE; LIVE VACCINE; PERTUSSIS VACCINE; SALMONELLOSIS VACCINE; SHIGELLA VACCINE; TYPHOID VACCINE; VIRUS VACCINE; ZINC;

ANTIBODY RESPONSE; BACTERIAL CELL; BACTERIAL VIRULENCE; CAMPYLOBACTER JEJUNI; CHILD DEVELOPMENT; CHILD HEALTH; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; CHOLERA; CLINICAL TRIAL; COGNITIVE DEVELOPMENT; CROSS REACTION; DEVELOPING COUNTRY; DIARRHEA; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG ADMINISTRATION ROUTE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSENTERY; ESCHERICHIA COLI; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOCOMPETENCE; IMMUNOGENICITY; LIQUID; MALNUTRITION; MOLECULAR CLONING; MORBIDITY; MUCOSA; NONHUMAN; ORAL REHYDRATION THERAPY; PATHOGENESIS; PHYSICAL DEVELOPMENT; PRIORITY JOURNAL; PROTECTION; REVIEW; ROTAVIRUS; SEROTYPE; SHIGELLA; TOXICITY; TYPHOID FEVER; VACCINATION; VIBRIO CHOLERAE;

EID: 17144390274     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.12.029     Document Type: Review

References (182)

1. World Health Organization. Development of vaccines against cholera and diarrhea due to enterotoxigenic Escherichia coli: memorandum from a WHO meeting. Bull WHO 1990;68:303-12.
2. C. Berne, J. Martines, I. de Zoysa, and R.I. Glass The magnitude of the global problem of diarrhoeal disease: a ten-year update Bull World Health Organ 70 1992 705 714
3. A.-M. Svennerholm, and D. Steele Progress in enteric vaccine development Best Pract Res Clin Gastroenterol 18 2004 421 445
4. World Health Organization. Programme for control of diarrhoeal diseases: ninth programme report 1992-1993. Geneva: World health Organization; 1994.
5. MJ.G. Farthing Diarrhoea: a significant worldwide problem Intern J Antimicrobial Agents 14 2000 65 69
6. T. Houndt, and H. Ochman Long-term shifts in patterns of antibiotic resistance in enteric bacteria Appl Environ Microbiol 66 12 2000 5406 5409
7. S.R. Moore, A.A. Lima, M.R. Conaway, J.B. Schorling, A.M. Soares, and R.L. Guerrant Early childhood diarrhea and helminthiases associate with long-term linear growth faltering Int J Epidemiol 30 6 2001 1457 1464
8. G. Bonfiglio, J. Simpore, S. Pignatelli, S. Musumeci, and M.L. Solinas Epidemiology of bacterial resistance in gastro-intestinal pathogens in a tropical area Int J Antimicrob Agents 20 5 2002 387 389
9. Institute of Medicine, New Vaccine Development, Establishing Properties: vol. II. Diseases of Importance in Developing Countries. Washington DC: National Academy Press 1986;8(2):131-35.
10. R.L. Guerrant, A.A. Lima, M. Barboza, S. Young, T. Silva, and L. Barrett Mechanisms and impact of enteric infections Adv Exp Med Biol 473 1999 103 112
11. R.L. Guerrant, J.B. Schorling, J.F. McAuliffe, and M.A. De Souza Diarrhea as a cause and effect of malnutrition: diarrhea prevents catch-up growth and malnutrition increases diarrhea frequency and duration Am J Trop Med Hyg 47 Suppl. 1 1992 28 35
12. R.L. Guerrant, M. Kosek, S. Moore, B. Lorntz, R. Brantley, and A.M. Aldo Lima: magnitude and impact of diarrheal diseases Arch Med Res 33 4 2002 351 355
13. R.E. Behrman, and V.C. Vaughan Nelson textbook of pediatrics 1987 W.B. Saunders Co. Philadelphia
14. S.L. Gorbach, and R. Edelman Travelers' diarrhea: National Institutes of Health consensus development conference. Introduction Rev Infect Dis 8 Suppl. 2 1986 109 110
15. K.C. Hyams, A.L. Bourgeois, B.R. Merrell, P. Rozmajzl, J. Escamilla, and S.A. Thornton Diarrheal disease during Operation Desert Sheild: a major cause of infectious disease morbidity among United States military personnel NEJM 325 1991 1423 1428
16. R.L. Haberberger Jr., and R.I. Walker Prospects and problems for development of a vaccine against diarrhea caused by Campylobacter Vaccine Res 3 1994 15 22
17. G. Dougan, H. Huett, and S. Clare Vaccines against human entric bacterial pathogens Br Med Bull 62 2002 113 123
18. D.N. Taylor, P. Echeverria, M.J. Blaser, C. Pitarangsi, N. Blacklow, and J. Cross Polymicrobial aetiology of travellers' diarrhoea Lancet 1 8425 1985 381 383
19. L.S. Bichile, K. Saraswati, U.R. Popat, S.A. Nanivadkar, and L.P. Deodhar Acute Campylobacter jejuni enteritis in 385 hospitalised patients J Assoc Phys India 40 3 1992 164 166
20. H. Petola, A. Siitonen, H. Kyronseppa, I. Simula, L. Mattila, and P. Oksanen Prevention of travelers diarrhoea by oral B-subunit/whole cell cholera vaccine Lancet 338 1991 1285 1289
21. I. Nachamkin M.J. Blaser L.S. Tompkins Campylobacter jejuni. Current status and future trends 1992 American Society for Microbiology Washington, DC 1 300
22. D.N. Taylor, and M.J. Blaser Campylobacter infections A.S. Evans P.S. Brachman Bacterial infections of humans. Epidemiology and control 1991 Plenum Medical Book Co. New York 151 172
23. N.J. Stern, and S.U. Kazmi Campylobacter jejuni M.P. Doyle Foodborne bacterial pathogens 1989 Marcel Dekker New York 71 110
24. B. Mishu, and M.J. Blaser Do you have Campylobacter in your future? West J Med 161 2 1994 186 187
25. M.C. Peterson Clinical aspects of Campylobacter jejuni infection in adults West J Med 161 2 1994 148 152
26. S. Kuroki, T. Saida, M. Nukina, T. Haruta, M. Yoshioka, and Y. Kobayashi Campylobacter jejuni strains from patients with Guillain-Barre syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues Ann Neurol 33 3 1993 243 247
27. B. Mishu, and M.J. Blaser Role of infection due to Campylobacter jejuni in the initiation of Guillain-Barre syndrome Clin Infect Dis 17 1 1993 104 108
28. J.W. Griffin, C.Y. Li, T.W. Ho, M. Tian, C.Y. Gao, M. Tian, C.Y. Gao, and P. Xue Pathology of motor-sensory axonal Guillain-Barre syndrome Ann Neurol 39 1 1996 17 28
29. K.L. Kotloff, J.P. Winickoff, B. Ivanoff, J.D. Clemens, D.L. Swerdlow, and P.J. Sansonetti Global burden of shigella infections: implications for vaccine development and implementation Bull WHO 77 1999 651 656
30. M.L. Bennish Potentially lethal complications of shigellosis Rev Infect Dis 13 4 1991 319 324
31. D.N. Taylor, L. Bodhidatta, and P. Echeveria Epidemiologic aspects of shigellosis and other causes of dysentary in Thailand Rev Infect Dis 13 Suppl. 4 1991 S226 S230
32. C. Ronsmans, M.L. Bennish, and T. Wierzba Diagnosis and management of dysentery by community health workers Lancet ii 1988 552 555
33. E.J. Gangarosa, D.R. Perea, L.J. Mata, C. Mendizabal-Morris, G. Cuzma, and L.B. Reller Epidemic shiga bacillus dysentary in Central America. II. Epidemiologic studies in J Infect Dis 122 1970 181 190
34. J.A. Frost, J. Vandepitte, B. Rowe, and E.J. Threlfall Plasmid characterisation in the investigation of an epidemic caused by multiply resistant Shigella dysenteriae type 1 Lancet ii 1981 1074 1076
35. A.A. Ries, J.G. Wells, D. Olivola, M. Ntakibirora, S. Nyandwi, and M. Ntibakivayo Epidemic Shigella dysenteriae type 1 in Burundi: pan resistance and implications for prevention J Infect Dis 169 1994 1035 1041
36. S.C. Pal Epidemic bacillary dysentery in West Bengal, India Lancet I 1984 1462
37. D.N. Taylor, and P. Echeverria Etiology and epidemiology of travelers' diarrhea in Asia Rev Infect Dis 8 2 1986 136 141
38. P. Shears A review of bacterial resistance to antimicrobial agents in tropical countries Ann Trop Paediatr 13 1993 219 226
39. JM.V. Packer An outbreak of dysentery in a day nursery and a school Commun Dis Rep 46 1983 3 4
40. G. Samonis, L. Elting, E. Skoulika, S. Maraki, and Y. Tselentis An outbreak of diarrhoeal disease attributed to Shigella sonnei Epidemiol Infect 112 2 1994 235 245
41. R.E. Black The epidemiology of cholera and enterotoxigenic E. coli diarrheal disease J. Holmgren A. Lindbergand R. Mollby Development of vaccines and drugs against diarrhea 1986 Studentlitteratur Lund, Sweden 23 32
42. D.A. Sack, and M. Cadoz Cholera vaccines SA. Plotkin WA. Orenstein Vaccines 1999 W.B. Saunders Co. PA 639 649
43. World Health Organization. Cholera vaccines. WHO position paper. Week Epidemiol Res 2001;76:117-24.
44. C.B. Felder, N. Vorlaender, B. Gander, H.P. Merkle, and H.U. Bertschinger Microencapsulated enterotoxigenic Escherichia and detached fimbriae for peroral vaccination of pigs Vaccine 19 7-8 2000 706 715
45. R.H. Reid, E.C. Boedeker, C.E. McQueen, D. Davis, L.Y. Tseng, and J. Kodak Preclinical evaluation of microencapsulated CFA/II oral vaccine against enterotoxigenic E. coli Vaccine 11 2 1993 159 167
46. J.H. Passwell, E. Harlev, S. Ashkenazi, C. Chu, D. Miron, and R. Ramon Safety and immunogenicity of improved Shigella O-specific polysaccharide protein conjugate vaccines in adults in Israel Infect Immun 69 3 2001 1351 1357
47. S. Ashkenazi, J.H. Passwell, E. Harley, D. Miron, R. Dagan, and N. Farzan Safety and immunogenicty of Shigella sonnei and Shigella flexneri 2a O specific polysaccharide conjugates in children J Infect Dis 179 6 1999 1565 1568
48. R. Chikwamba, J. Cunnick, D. Hathaway, J. McMurray, H. Mason, and K. Wang A functional antigen in a practical crop: LT-B producing maize protects mice against Escherichia coli heat labile enterotoxin (LT) and cholera toxin (CT) Transgenic Res 11 5) 2002 479 493
49. H.S. Mason, J.M. Ball, J.J. Shi, X. Jiang, M.K. Estes, and C.J. Arntzen Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice Proc Natl Acad Sci USA 93 11 1996 5335 5340
50. C.J. Artnzen Edible vaccines Pub Health Rep 112 3 1997 190 197
51. G.M. Glenn, D.N. Taylor, X. Li, S. Frankel, A. Montemarano, and C.R. Alving Transcutaneous immunization: a human vaccine delivery strategy using a patch Nat Med 6 12 2000 1403 1406
52. J. Holmgren, and A.M. Svennerholm Development of oral vaccines against cholera and enterotoxigenic Esherichia coli diarrhea Scand J Infect Dis 76 Suppl. 1990 47 53
53. S.J. Savarino, E.R. Hall, S. Bassily, T.F. Wierzba, F.G. Youssef, and L.F. Peruski Introductory evaluation of an oral, killed whole cell enterotoxigenic Esherichia coli plus cholera toxin B-subunit vaccine in Egyptian infants Pediatr Infect Dis J 21 4 2002 322 330
54. F.R. Noriega, F.M. Liao, D.R. Maneval, S. Ren, S.B. Formal, and M.M. Levine Strategy for cross-protection among Shigella flexneri serotypes Infect Immun 67 1999 782 788
55. A.M. Svennerholm, J. Holmgren, and D.A. Sack Development of oral vaccines against enterotoxigenic Escherichia coli diarrhoea Vaccine 7 1989 196 198
56. C.M. Ahren, and A.M. Svennerholm Synergistic protective effect of antibodies against Escherichia coli entertoxin and colonization factor antigens Infect Immun 38 1 1982 74 79
57. M.B. Cohen, R.A. Giannella, J. Bean, D.N. Taylor, S. Parker, and A. Hoeper Randomized, controlled human challenge study of the safety, immunogenicty, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine Infect Immun 70 4 2002 1965 1970
58. M.M. Venkatesan, A.B. Hartman, J.W. Newland, V.S. Ivanova, T.L. Hale, and M. McDonough Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine J Infect Immundkjdot 70 6 2002 2950 2958
59. A. Sinha, S. Sazawal, R. Kumar, S. Sood, V.P. Reddaiah, and B. Singh Typhoid fever in children less than 5 years Lancet 354 1999 734 737
60. A.Z. Kapikian, M.K. Estes, and R.M. Chanock Norwalk group of viruses B.N. Fields D.M. Knipe P.M. Howley R.M. Chanock J.L. Melnick T.P. Monath B. Roizman S.E. Straus Virology 2 1996 Lippincott-Raven New York 783 810
61. R.A. Guerreo, J.M. Ball, S.S. Krater, S.E. Pacheco, J.D. Clements, and M.K. Estes Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses J Virol 75 20 2001 9713 9722
62. J.M. Ball, M.E. Hardy, R.L. Atmar, M.E. Conner, and M.K. Estes Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice J Virol 72 1998 1343 1345
63. J.M. Ball, D.Y. Graham, A.R. Opekun, M.A. Gilger, R.A. Guerrero, and M.K. Estes Recombinant Norwalk virus-like particles given orally to volunteers: phase I study Gastroenterology 2117 1 1999 40 48
64. A.H. Choi, M.M. McNeal, M. Basu, J.A. Flint, S.C. Stone, and J.D. Clements Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses Vaccine 20 2002 3310 3321
65. K. Yang, S. Wang, K.-O. Chang, S. Lu, L.J. Saif, and H.B. Greenberg Immune responses and protection obtained with rotavirus VP6 DNA vaccines given by intramuscular injection Vaccine 19 2001 3285 3291
66. J. Yu, F. Cassels, T. Scharton-Kersten, S.A. Hammond, A. Hartman, and E. Angov Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli Infect Imm 70 3 2002 1056 1068
67. M. John, E.A. Bridges, A.O. Miller, S.B. Calderwood, and E.T. Ryan Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies Vaccine 20 2002 2720 2726
68. R.W. Frenck Jr., and J. Clemens Helicobacter in the developing world Microbes Infect 5 8 2003 705 713
69. M.K. Bhan, R. Bahl, S. Sazawal, A. Sinha, R. Kumar, and D. Mahalanabis Association between Helicobacter pylori infection and increased risk of typhoid fever J Infect Dis 186 2002 1857 1860
70. L. Cárdenas, U. Dasgupta, and J.D. Clements Influence of strain viability and antigen dose on the use of attenuated mutants of Salmonella as vaccine carriers Vaccine 12 1994 833 840
71. J.C. Paton, T.J. Rogers, R. Morona, and A.W. Paton Oral administration of formaldehyde-killed recombinant bacteria expressing a mimic of the shiga toxin receptor protects mice from fatal challenge with shiga-toxigenic Escherichia coli Infect Immun 69 3 2001 1389 1393
72. W. Lubitz, A. Witte, F.O. Eko, M. Kamal, W. Jechlinger, and E. Brand Extended recombinant bacterial ghost system J Biotechnol 73 1999 261 273
73. F.O. Eko, M.P. Szostak, G. Wanner, and W. Lubitz Production of Vibrio cholerae ghosts (VCG) by expression of a cloned phage lysis gene: potential for vaccine development Vaccine 12 1994 1231 1237
74. A.G. Haselberger, G. Kohl, D. Felnerova, U.B. Mayr, S. Furst-Ladani, and W. Lubitz Activation, stimulation, and uptake of bacterial ghosts in antigen presenting cells J Biotech 83 2000 57 66
75. K. Jalava, F.O. Eko, E. Reidmann, and W. Lubitz Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery Expert Rev Vaccines 2 2003 89 95
76. F.O. Eko, E.Y. Schukovskaya, V.V. Lotzmanova, N.V. Firsyova, V.V. Firstova, N.V. Emalyanova, and S.N. Klueva Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits Vaccine 21 2003 3663 3674
77. F.O. Eko, A. Hensel, S. Bunka, and W. Lubtiz Immunogenicity of Vibrio cholerae ghosts following intraperitoneal immunization of mice Vaccine 12 14 1994 1330 1334
78. F.M. Rollwagen, N.D. Pacheco, J.D. Clements, O. Pavlovskis, D.M. Rollins, and R.I. Walker Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant Vaccine 11 1993 1316 1320
79. S. Baqar, L.A. Applebee, and A.L. Bourgeois Immunogenicity and protective efficacy of a prototype Campylobacter killed whole cell vaccine in mice Infect Immun 63 1995 3731 3735
80. Tribble D, Baqar S, Faix D, Liss A, Nielsen R, Porter C, et al. Modified Escherichia coli heat-labile toxin (LT[R192G]) adjuvant dose-range study of an oral, inactivated whole cell Campylobacter (CWC) vaccine in volunteers. Modern Vaccines, Adjuvants and Delivery System. Dublin, Ireland: 4-6 June 2004.
81. A.B. Hartman, L. Van De Verg, and M.M. Venkatesan Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines Infect Immun 67 1999 5841 5847
82. M.K. Chakrabarti, J. Bhattacharya, M.K. Bhattacharya, G.B. Nair, S.K. Bhattacharya, and D. Mahalanabis Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in a rabbit model of shigellosis Acta Paediatr 88 1999 161 165
83. C.H. Guillobel, J.I. Carinhanha, L. Cardeanas, J.D. Clements, D.F. de Almeida, and L.C. Ferreira Adjuvant activity of a nontoxic mutant of Escherichia coli heat labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live Salmonella enterica serovar Typhimurium vaccine strain Infect Immun 68 7 2000 4349 4353
84. K.L. Kotloff, M.B. Sztein, S.S. Wasserman, G.A. Losonsky, S.C. DiLorenzo, and R.I. Walker Safety and immunogenicity of oral inactivated whole cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection Infect Immun 69 6 2001 3581 3590
85. Tribble DR, Baqar S, Oplinger ML, Bourgeois AL, Clements JD, Pazzaglia G, et al. Safety and immunogenicity of an oral, inactivated whole cell Campylobacter vaccine co-administered with modified Escherichia coli heat-labile enterotoxin (LTR1926) adjuvant in volunteers. Interscience Conference on Antimicrobial Agents Chemotherapy. Toronto, Canada; 1997.
86. A.M. Krieg CpG DNA: a novel immunomodulator Trends Microbiol 7 2 1999 64 65
87. W. Jiang, H.J. Baker, and B.K. Smith Mucosal immunization with Helicobacter, CpG DNA, and cholera toxin is protective Infect Immun 21 2003 40 46
88. Zinc Investigator's Collaborative Group Z.A. Bhutta, R.E. Black, K.H. Brown, J.M. Gardner, S. Gore, and A. Hidayat Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials J Pediatr 135 6 1999 689 697
89. T.H. Karlsen, H. Sommerfelt, S. Klomstad, P.K. Andersen, T.A. Strand, and R.J. Ulvik Intestinal and systemic immune responses to an oral cholera toxoid B-subunit whole cell vaccine administered during zinc supplementation Infect Immun 71 7 2003 3909 3913
90. M.J. Albert, F. Qadri, M.A. Washed, T. Ahmed, A.S. Rahman, and F. Ahmed Supplementation with zinc, but not Vitamin A, improves the seroconversion to vibriocidal antibody in children given an oral cholera vaccine J Infect Dis 187 6 2003 909 913
91. B. Haneberg, Berstad AKH, and J. Holst Bacteria-derived particles as ajuvants for non-replacing nasal vaccines Adv Drug Deliv Rev 51 2001 143 147
92. M.M. Levine, J.B. Kaper, D.A. Herrington, J. Ketley, G. Losonsky, and C.O. Tackett Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR Lancet 2 1989 467 470
93. S.J. Cryz Jr., M.M. Levine, J.B. Kaper, E. Furer, and B. Althaus Randomized double blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103HgR in Swiss adults Vaccine 8 1990 577 580
94. R. Germanier, and E. Furer Virulence and immunogenicity of Salmonella typhimurium rough mutants Pathol Microbiol 38 1 1972 41
95. C. Ferreccio, M.M. Levine, H. Rodriguez, and R. Contreras Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area J Infect Dis 59 4 1989 766 769
96. A. Kantele Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine Vaccine 8 4 1990 321 326
97. J. Banchereau, and R.M. Steinman Dendritic cells and the control of immunity Nature 392 6673 1998 245 252
98. A.S. McWilliam, D. Nelson, J.A. Thomas, and P.G. Holt Rapid dendritic cell recruitment is a hallmark of the acute inflammatory response at mucosal surfaces J Exp Med 179 4 1994 1331 1336
99. L.A. Bergmeir, L. Tao, Gearing AJM, S. Adams, and T. Lehner Comparison of IgA antibodies in vaginal and rectal fluids, serum and saliva following immunization of genital and gut-associated lymphoid tissue Proceedings of the Seventh International Congress Mucosal Immunology Prague, Czechoslavakia 1992 23
100. J.G. Nedrud, X. Liang, N. Hague, and M.E. Lamm Combined oral/nasal immunization protects mice from Sendai virus infection J Immun 139 1987 3484 3492
101. B. Haneberg, D. Kendall, H.M. Amerogen, F.M. Apter, J.-P. Kraehenbuhl, and M.R. Neutra Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces Infect Immun 62 1994 15 23
102. A.K.H. Berstad, J. Holst, L.O. Froholm, I.L. Haugen, E. Wedege, and B. Haneberg A nasal whole cell pertussis vaccine can induce specific systemic and cross-reactive mucosal antibody responses in human volunteers J Med Microbiol 49 2000 157 163
103. R.I. Walker New strategies for using mucosal vaccination to achieve more effective immunization Vaccine 12 1994 387 400
104. J.M. Langman, and R. Rowland The number and distribution of lymphoid follicles in the human large intestine J Anat 149 1986 189 194
105. P.L. Ogra, and D.T. Karzon Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine J Immunol 102 6 1969 1423 1430
106. K.-C. Bergman, and R.H. Waldman Oral immunization with influenza virus: experimental and clinical studies Curr Top Microbiol Immunol 146 1989 83
107. B.D. Forrest, Sherman DJC, and J.T. LaBrooy Specific immune response in humans following rectal delivery of live typhoid vaccine Vaccine 8 1990 209 212
108. M. Jertborn, I. Nordstrom, A. Kilander, C. Czerkinsky, and J. Holmgren Local and systemic immune responses to rectal administration of recombinant cholera toxin B-subunit in humans Infect Immun 2001 4125 4128
109. J. Nedrud, N. Sigmund, E. Brunschwig, and M. Lamm Oral immunization against respiratory viruses in mice Proceedings of the Seventh International Congress Mucosal Immunology Prague, Czechoslavakia 1992 170
110. A.-M. Svennerholm, L.A. Hansou, J. Holmgren, B.S. Lindlad, B. Milsson, and F. Quereshi Different secretory Immunoglobulin A antibody responses to cholera vaccination in Swedish and Pakistani women Infect Immun 30 1980 427 430
111. B.D. Forrest, J.T. Laborooy, C.E. Dearlove, and DJ.C. Shearman Effect of parental immunization on the intestinal immune response to Salmonella typhi Ty21a Infect Immun 60 1992 465 471
112. D.F. Keren, R.A. McDonald, and J.L. Carey Combined parenteral and oral immunization results in an enhanced mucosal immunoglobulin A response to Shigella flexneri Infect Immun 56 1988 910 915
113. D.A. Sack, J. Shimko, R.B. Sack, J.G. Gomes, K. MacLeod, and D. O'Sullivan Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers Infect Immun 65 1997 2107 2111
114. J.D. Clemens, M. Jertborn, D. Sack, B. Stanton, J. Holmgren, and M.R. Khan Effect of neutralization of gastric acid on immune responses to an oral B-subunit, killed whole cell cholera vaccine J Infect Dis 154 1986 175 178
115. M.P. Flanagan, G. Battisti, and J.G. Michael Oral administration of Escherichia coli in enteric coated microparticles induces serum antibodies against lipopolysaccharide antigens J Endotoxin Res 3 6 1996 481 489
116. M.M. Levine, C. Ferreccio, S. Cryz, and E. Orbitz Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomized controlled field trial Lancet 336 8720 1990 891 894
117. R.I. Glass, B.J. Stoll, M.I. Huq, M.J. Struelens, M. Blaser, and A.K. Kibriya Epidemiologic and clinical features of endemic campylobacter jejuni infection in Bangladesh J Infect Dis 148 1983 292 296
118. R.E. Black, M.M. Levine, K.H. Brown, M.L. Clements, and G. Lopez de Romana Immunity to Campylobacter jejuni in man A.D. Pearson M.B. Skirrow H. Lior B. Rowe Campylobacter III 1985 Public Health Laboratory Service London 129
119. P.V. Martin, J. Mathiot, J. Ipero, M. Kirimat, A.J. Georges, and M.-C. Georges-Courbot Immune response to Campylobacter jejuni and Campylobacter coli in a cohort of children form birth to 2 years of age Infect Immun 57 1989 2542 2546
120. R.E. Black, M.M. Levine, M.L. Clements, J.P. Hughes, and M.J. Blaser Experimental Campylobacter jejuni infection in humans J Infect Dis 157 1988 472 479
121. E. McSweegan, D.H. Burr, and R.I. Walker Intestinal mucus gel and secretory antibody are barriers to Campylobacter jejuni adherence to INT 407 cells Infect Immun 55 1987 1431 1435
122. R.J. Johnson, C. Nolan, S.P. Wang, W.R. Shelton, and M.S. Blaser Persistant Campylobacter jejuni infection in an immunocompromised patient Ann Intern Med 100 1984 832 834
123. I. Melamed, Y. Bujanover, Y.S. Igra, D. Schwartz, V. Zakuth, and Z. Sprner Campylobacter enteritis in normal and deficient children Am J Dis Child 1371 1983 752 753
124. S.D. Mills, and W.C. Bradbury Human antibody response to outer membrane proteins of Campylobacter jejuni during infection Infect Immun 43 2 1984 739 743
125. D. Newell, H. McBride, and A.D. Pearson The identification of outer membrane proteins and flagella of Campylobacter jejuni J Gen Microbiol 130 1984 1201 1208
126. L. Hu, and D.J. Kopecko Campylobacter jejuni 81-176 associates with microtubules and dynein during invasion of human intestinal cells Infect Immun 67 8 1999 4171 4182
127. C.C. Grant, M.E. Konkel, W. Cieplak Jr., and L.S. Tompkins Role of flagella adherence, internalization, and translocation of Campylobacter jejuni in nonpolarized and polarized epithelial cell cultures Infect Immun 61 5 1993 1764 1771
128. S.M. Logan, and T.J. Trust Location of epitopes on Campylobacter jejuni flagella J Bacteriol 168 2 1986 739 745
129. M.E. Power, P. Guerry, W.D. McCubbin, C.M. Kay, and T.J. Trust Structural and antigenic characteristics of Campylobacter coli FlaA flagellin J Bacteriol 176 1994 3303 3313
130. S.M. Logan, and T.J. Trust Outer membrane characteristics of Campylobacter jejuni Infect Immun 38 3 1982 898 906
131. M.J. Blaser, J.A. Hopkins, and M.L. Vasil Campylobacter jejuni outer membrane proteins are antigenic for humans Infect Immun 43 3 1984 986 993
132. Pei ZH, Ellison RT, 3rd, Blaser MJ. Identification, purification, and characterization of major antigenic proteins of Campylobacter jejuni. J Biol Chem 1991;266925:16363-9.
133. H. Lior, D.L. Woodward, J.A. Edgar, L.J. Laroche, and P. Gill Serotyping of Campylobacter jejuni by slide agglutination based on heat-labile antigenic factors J Clin Microbiol 15 1982 761 768
134. J.A. Majde, O. Pavlovskis, S. Baqar, J.M. Katz, R.I. Walker, and J.D. Clements Escherichia coli heat-labile enterotoxin, an oral adjuvant for protection against mucosal pathogens P.D.E.S. Stewart-Tull Adjuvants - theory and practical applications 1995 John Wiley and Sons Inc. NY 337 351
135. R.I. Walker, and J.D. Clements Use of heat-labile toxin of enterotoxigenic Escherichia coli to facilitate mucosal immunization Vaccine Res 2 1 1993 1 10
136. O.R. Pavlovskis, D.M. Rollins, R.L. Haberberger Jr., A.E. Green, L. Habash, and S. Strocko Significance of flagella in colonization resistance of rabbits immunized with Campylobacter spp Infect Immun 59 1991 2259 2264
137. B.L. Dickinson, and J.D. Clements Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity Infect Immun 63 5 1995 1617 1623
138. L.H. Lee, E. Burg, S. Baqar, A.L. Bourgeois, D.H. Burr, and C.P. Ewing Evaluation of a truncated recombinant flagellin subunit vaccine against Campylobacter jejuni Infect Immun 67 11 1999 5799 5805
139. A.A. Lindberg, S. Haeggman, K. Karlsson, P.D. Cam, and D.D. Trach The humoral antibody response to Shigella dysenteriae type 1 infection, as determined by ELISA Bull WHO 62 1984 597 606
140. E. Ekwall, and A.A. Lindberg Shigella flexneri O-antigen specific enzyme immunoassay; class-specific antibody titres against lipopolysaccharide antigen in adult Swedes with bacillary dysentery Serodiag Immunother Infect Dis 2 1988 103 111
141. E. Ekwall, P.D. Cam, D.D. Trach, A. Taube, and A.A. Lindberg Shigella flexneri O-antigen specific immunoassay: class-specific antibody titres against lipopolysaccharide antigens in healthy Vietnamese and Swedish populations Serodiagn Immunother 2 1988 47 61
142. E. Ekwall, P.D. Cam, N. Chan, L.K. Phu, D.D. Trach, and A.A. Lindberg Shigella flexneri O-antigen specific enzyme immunoassay; a prospective study of class-specific antibody titres against lipopolysaccharide antigens in Vietnamese children and adults with serotype 1b and 2a dysentery Serodiagn Immunother 2 1988 171 182
143. E.V. Oaks, T.L. Hale, and S.B. Formal Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp Infect Immun 53 1986 57 63
144. R.A. Oberhelman, D.J. Kopecko, E. Salazar-Lindo, E. Gotuzzo, J.M. Buysse, and M.M. Venkatesan Prospective study of systemic and mucosal immune response in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides Infect Immun 59 1981 2341 2350
145. D.M. Mel, B.L. Arsic, B.D. Nikoloc, and M.L. Radovanic Studies on vaccination against bacillary dysentery. 4. Oral immunization with live monotypic and combined vaccines Bull WHO 39 1968 375 380
146. H.L. DuPont, R.B. Hornick, M.J. Snyder, J.P. Libonati, S.B. Formal, and E.J. Gangarosa Immunity in shigellosis. I. Response of man to attenuated strains of Shigella J Infect Dis 125 1972 5 11
147. G.H. Lowell, R.P. MacDermott, P.L. Summers, A.A. Reeder, MJ. Bertovich, and S.B. Formal Antibody-dependent cell-mediated antibacterial activity; K lymphocytes, monocytes, and granulocytes are effective against Shigella J Immunol 125 1980 2778 2784
148. S. Barzu, A. Fontaine, P.J. Sansonetti, and A. Phalipon Induction of local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate; implications for use of IpaC as a protein carrier Infect Immun 64 1996 1190 1196
149. T.S. Coster, C.W. Hoge, L.L. van de Verg, A.B. Hartman, E.V. Oaks, and M.M. Venkatesan Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602 Infect Immun 67 7 1999 3437 3443
150. J.F. Viret, S.J. Cryz Jr., A.B. Lang, and D. Favre Molecular cloning and characterization of the genetic determinants that express the complete Shigella serotype D (Shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains Mol Microbiol 7 2 1993 239 252
151. J.F. Viret, S.J. Cryz, and D. Favre Expression of Shigella sonnei lopopolysaccharide in Vibrio cholerae Mol Microbiol 19 5 1996 949 963
152. D. Favre, S.J. Cryz Jr., and J.F. Viret Development of Shigella sonnei live oral vaccines based on defined rfbInaba deletion mutants of Vibrio cholerae expressing the Shigella D O polysaccharide Infect Immun 64 2 1996 576 584
153. D.Q. Xu, J.O. Cisar, N. Ambulos Jr., D.A. Burr, and D.J. Kopecko Molecular cloning and characterization of genes for Shigella sonnei form I O polysaccharide: proposed biosynthetic pathway and stable expression in a live salmonella vaccine vector Infect Immun 70 8 2002 4414 4423
154. D.F. Keren, H.H. Collins, P. Gemski, P.S. Holt, and S.B. Formal Role of antigen form in development of mucosal immunoglobulin A response to Shigella flexneri antigens Infect Immun 31 1981 1193 1202
155. S. Peppoloni, P. Ruggiero, M. Contorni, M. Morandi, M. Pizza, and R. Rappuoli Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines Expert Rev Vaccines 2 2003 285 293
156. McKenzie R, Nabors GS, Carpenter C, Gomes G, Forbes E, Liss A, et al. Safety and immunogenicity of an oral, inactivated, whole cell vaccine for Shigella sonnei (SsWC). Sixth Ann Conf Vaccine Res 2004;S8:41.
157. C. Ahren, M. Jertborn, and A.-M. Svennerholm Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood Infect Immun 66 7 1998 3311 3316
158. A.M. Svennerholm, C. Wenneras, J. Holmgren, and M.M. McConnell Roles of different coli surface antigens of colonization factor antigen II in colonization by and protective immunogenicity of enterotoxigenic Escherichia coli in rabbits Infect Immun 58 2 1990 341 346
159. J.D. Clemens, D.A. Sack, J.R. Harris, J. Chakraborty, P.K. Neogy, and B. Stanton Cross-protection by B-subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial J Infect Dis 158 1988 372 377
160. M. Jertborn, C. Ahren, J. Holmgren, and A.M. Svennerholm Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli vaccine Vaccine 16 1998 255 260
161. S.J. Savarino, E.R. Hall, S. Bassily, F.M. Brown, F. Youssef, and T.F. Wierzba Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B-subunit vaccine: results of the initial evaluation in children J Infect Dis 179 1999 107 114
162. E.M. Barry, Z. Altboum, G. Losonsky, and M.M. Levine Immune responses
163. Z. Altboum, E.M. Barry, G. Losonsky, J.E. Galen, and M.M. Levine Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enteroxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection Infect Immun 69 5 2001 3150 3158
164. Z. Altboum, M.M. Levin, J.E. Galen, and E.M. Barry Genetic characterization and immunogenicity of coli surface antigen 4 from enterotoxigenic Escherichia coli when it is expressed in a Shigella live-vector strain Infect Immun 71 3 2003 1352 1360
165. H. Koprowski, M.M. Levine, R.J. Anderson, G. Losonsky, M. Pizza, and E.M. Barry Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli Infect Immun 68 9 2000 4884 4892
166. F.R. Noriega, G. Losonsky, J.Y. Wang, S.B. Formal, and M.M. Levine Further characterization of aroA virG Shigella, flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli Infect Immun 64 1996 23 27
167. A.K. Turner, T.D. Terry, D.A. Sack, P. Londono-Arcila, and M.J. Darsley Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and premliminary studies of safety and immunogenicity in humans Infect Immun 69 8 2001 49669 49679
168. M.M. Levine, J.B. Kaper, R.E. Black, and M.L. Clements New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development Microbiol Rev 47 1983 510 550
169. J.D. Clemens, D.A. Sack, M.R. Rao, J. Chakraborty, M.R. Khan, and B. Kay Evidence that inactivated oral cholera vaccines both prevent and mitigate Vibrio cholerae 01 infections in a cholera-endemic area J Infect Dis 166 1992 1029 1034
170. D.A. Sack, J.D. Clemens, S. Huda, J.R. Harris, M.R. Khan, and J. Chakraborty Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh J Infect Dis 164 1991 407 411
171. J. Nesper, N. Sigmund, C.M. Lauriano, A. Kraiss, K.E. Klose, and J. Reidl Role of Vibrio cholerae O139 surface polysaccharides in intestinal colonization Infect Immun 70 11 2002 5990 5996
172. M.J. Albert, K. Alam, M. Ansaruzzaman, S. Huda, and D.A. Sack Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR J Infect Dis 169 1994 230 231
173. F. Qadri, G. Mohi, J. Hossain, T. Azim, A.M. Khan, and M.A. Salam Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1 Clin Diagn Lab Immunol l2 1995 685 688
174. F. Qadri, C. Wenneras, M.J. Albert, J. Hossain, K. Mannoon, and Y.A. Begum Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1 Infect Immun 65 1997 3571 3576
175. A.M. Svennerholm, and J. Holmgren Synergistic protective effect rabbits immunization with Vibrio cholerae lipopolysaccahride and toxin/toxoid Infect Immun 13 1976 735 740
176. R.E. Black, M.M. Levine, M.L. Clemens, C.R. Young, A.M. Svennerholm, and J. Holmgren Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B-subunit of cholera toxin Infect Immun 55 1987 1116 1120
177. J.D. Clemens, D.A. Sack, J.R. Harris, J. van Loon, F. Chakraborty, and M.R. Ahmed Field trial of oral cholera vaccines in Bangladesh: results of a three-year follow-up Lancet 335 8684 1990 270 273
178. D.D. Trach, P.D. Cam, N.T. Ke, M.R. Rao, D. Dinh, and P.V. Hang Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam Bull WHO 80 2002 2 8
179. D.D. Trach, J.D. Clemens, N.T. Ke, H.T. Thuy, V.D. Son, and D.G. Canh Field trial of a locally produced, killed oral cholera vaccine in Vietnam Lancet 349 1997 231 235
180. S. Migasena, P. Pitisuttitham, B. Prayurahong, P. Suntharasami, W. Supanaranond, and V. Desakom Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults Infect Immun 57 1989 3261 3264
181. J.M. Kyd, and A.W. Cripps Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: an overview Vaccine 17 1999 1775 1781
182. Foxwell AR, Cripps AW, Dear, KB. Haemophilus influenzae oral whole cell vaccination for prevention of acute exacerbations of chronic bronchitis. Cochrane Database Sys Rev 2003;3:CD001958.